XSpray Pharma AB (OSTO:XSPRAY) Other Financing: kr-7.53 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XSPRAY XSpray Pharma AB OSTO:XSPRAY
29 GF Score
Price kr16.88
! 1 Warning Sign
View Full Analysis

What is XSpray Pharma AB Other Financing?

XSpray Pharma AB OSTO:XSPRAY +1.44% 29 Other Financing is kr-7.53 Mil as of Mar. 2026. GuruFocus rates OSTO:XSPRAY with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

XSpray Pharma AB's Other Financing for the three months ended in Mar. 2026 was kr0.00 Mil.

XSpray Pharma AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr-7.53 Mil.

XSpray Pharma AB Other Financing Historical Data

* Premium members only.

The historical data trend for XSpray Pharma AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB Other Financing Chart

XSpray Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -4.88 -26.20 -21.52 -7.66

XSpray Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 0.00 -7.52 -0.00 0.00
OSTO:XSPRAY
29GF Score
XSpray Pharma AB OSTO:XSPRAY
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XSpray Pharma AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-7.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr-7.53 Mil mean?
XSpray Pharma AB (OSTO:XSPRAY) has a Other Financing of kr-7.53 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for XSpray Pharma AB and its competitors.
Is XSpray Pharma AB's Other Financing too high?
XSpray Pharma AB's current Other Financing is kr-7.53 Mil. Overall, XSpray Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Other Financing compare to VRTX and REGN?
XSpray Pharma AB's Other Financing of kr-7.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for XSpray Pharma AB and its competitors. XSpray Pharma AB's current Other Financing is kr-7.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (OSTO:XSPRAY) has a current Other Financing of kr-7.53 Mil. The current Other Financing is kr-7.53 Mil. XSpray Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For XSpray Pharma AB (OSTO:XSPRAY), the current Other Financing is kr-7.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XSpray Pharma AB Business Description

Other Exchanges 0GHZ:UK6XP:Germany
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
29GF Score

Get the complete analysis for OSTO:XSPRAY

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr16.88
Price